Early results of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial showed that, by 30 days, 33 147% of 224 patients in the stenting group and 58% of 227 patients in the medical group had died or had a stroke percentages are product limit estimates, but provided insufficient data to establish whether stenting. Intracranial angioplasty and stenting before and after. Pdf effect of a balloonexpandable intracranial stent vs. The prevalence of 5099% symptomatic intracranial stenosis increases steeply with age in predominantly caucasian patients with transient ischaemic attack and minor ischaemic stroke. Is the future of symptomatic intracranial atherosclerotic.
Background and purpose a multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis icas combined with poor collaterals in china showed that the shortterm safety and efficacy of stenting was acceptable. Stenting versus aggressive medical therapy for intracranial. Finally, one of the most significant criticisms of the sammpris trial was that half of the patients in the trial. However, it remained uncertain whether the low event rate could be of a long term. Interestingly, the authors further analysed the outcome for those patients who met the sammpris criteria from the wasid trial. Nov 28, 2016 beside the sammpris trial, three other low recruiting trials were cited, including a chinese study of 35 patients, which was translated from chinese into german language exclusively for this report. Cpd was the neurointerventional pi initially and then became the neurointerventional copi after df joined the study executive committee.
The absorb iii findings come on the heels of the sammpris trial, which clearly demonstrated better outcomes with aggressive medical management for symptomatic intracranial stenosis compared with. Details about the study design, patient enrollment, and followup. Outline describe the epidemiology of intracranial stenosis. Sammpris trial was designed to assess whether percutaneous transluminal angioplasty and stenting ptas. The aggressive medical therapy based on the sammpris trial and a. At the end of the study, with a median followup of 32 months, the rate of. The study design for the sammpris trial has been published previ ously. Clopidogrel plus aspirin for symptomatic intracranial atherosclerotic. All books on are public domain texts and free to download as pdf. The 30day rate of stroke or death in the ptas group 14. Outcome in patients previously on antithrombotic therapy.
The cadiss trial is, to our knowledge, the first randomized clinical trial in the treatment of carotid and vertebral dissection that recruited the target and had complete followup of all patients to 1 year. How recent data have impacted the treatment of internal. For more, you may enjoy the mobile app stroke trials, or this brief overview by the university of pittsburgh residency program. Mechanisms of stroke after intracranial angioplasty and. Aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris. Click on acrobat pro dc, and select uninstall from the menu. Does the stenting versus aggressive medical therapy trial. The randomised multicentre study stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris showed 14. Here are just a few landmark neurology trials and articles every resident should know to keep up to date on important guidelines. End of intracranial stenting for atherosclerosis or. However, the risk of recurrent stroke on intensive medical treatment of symptomatic intracranial stenosis is consistent with the two previous randomised controlled trials in younger cohorts, supporting the. Primary angioplasty without stenting for symptomatic, high.
Entrance into the trial required the presence of a. Oral abstract presented at the 2012 international stroke. China angioplasty and stenting for symptomatic intracranial. The experience of treating icad in china, gained over the last two decades, is very rich and promising. Landmark neurology trials and papers steven gangloff, md. Expert pdf editor x64 for windows xp,vista,7,8 64bit and later. Finally, one of the most significant criticisms of the sammpris trial was that half of the patients in the trial were treated.
Mic is the principal investigator pi for the sammpris trial. Compress pdf docs to reduce file size or convert them to word, excel, powerpoint or jpg without other dependencies. Design, setting, and participants a post hoc analysis of patients in the medical arm only of the sammpris trial. Rigorous anaesthesia management protocol for patients with. Benefit of max medical management over stent for secondary stroke prevention in intracranial atherosclerosis. Outcome of patients in the sammpris trial who had failed antithrombotic therapy at study enrollment. The patients enrolled in the study had all previously survived. In intracranial artery stenosis, adding angioplasty and. Patients with symptomatic stenosis of intradural arteries are at high risk for subsequent stroke. Design of the vitesse intracranial stent study for ischemic. The stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris study is the first stroke prevention trial to include protocoldriven intensive management of multiple risk factors.
Results from the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial. Multicenter prospective trial of stent placement in patients. Randomized trial of patients in two predetermined strata based on the severity of carotid stenosis 30 to 69 percent and 70 to 99 percent who had had a hemispheric or retinal transient. Enrollment occurred between october 2008 and april 20 and included 227 patients. Length of stenosis and location were not used as stratifying features. The efficacy of angioplasty and stenting for patients with symptomatic intracranial atherosclerotic disease was recently evaluated in the stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris trial. Stenosis sammpris trial are listed in the supplementary appendix, available at.
Protocol for a prospective, multicentre registry study of. Aggressive medical treatment with or without stenting in high. In our opinion, a short segment symmetric petrous carotid artery stenosis has a very different procedural risk profile compared to a long segment asymmetric basilar artery stenosis. The periprocedural stroke rate in the sammpris trial because of perforator occlusion was 5.
Interventions the sammpris trial compared stenting with aggressive medical. More articles will be added periodically, so please check back. Intensive medical therapy in the sammpris trial consisting of aspirin, 325 mgday, for entire followup. Introduction the sammpris trial suggested that aggressive treatment was superior to endovascular stenting in patients with severe symptomatic intracranial atherosclerotic stenosis icas due to high complication rates in patients in the stenting group.
The sammpris trial evaluated the use of the wingspan stent system in a similar highrisk patient population as the vissit study. On the basis of the high 1month stroke andor death 14. In contrast, clinical experts tend to use welldesigned observational studies involving homogeneous populations and often scrutinize the. The results of the stenting versus aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris study showed a 5. This finding differs from the results of two recent trials comparing warfarin target inr, 2. The randomised multicentre study stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris.
Type and duration of exercise in the sammpris trial ncbi nih. Astrazeneca supplied rosuvastatin, study devices supplied by stryker, 3 rd party monitoring of sites by stryker. The stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial was designed to assess whether percutaneous transluminal angioplasty and stenting ptas plus aggressive medical treatment is more effective than aggressive medical treatment alone in highrisk patients with this disease. Sammpris randomized patients with 70 to 99% ic artery stenosis. Since the sammpris trial, stenting is no longer recommended as primary treatment. Relationship between vascular risk factors and location of. The new standard for performance of intracranial angioplasty and.
In this trial vissit vitesse stent ischemic therapy, which was initiated soon after the start of sammpris, we examined percutaneous transluminal balloon angioplasty with stenting in symptomatic intracranial stenosis, but differed in its design, sample size, and type of intracranial stent used. In the stenting and medical cohorts of the stenting and aggressive medical management for the prevention of recurrent ischemic stroke sammpris trial, we compared kaplanmeier km curves for the primary endpoint any stroke or death within 30 days of enrollment or ischemic stroke in the territory beyond 30 days using the logrank test and the percentages of patients achieving. Astrazeneca supplied rosuvastatin, study devices supplied by stryker, 3 rd party monitoring. Although the stenting versus aggressive medical therapy for intracranial arterial stenosis sammpris trial showed that medical therapy alone was superior to stenting plus medical therapy for preventing recurrent strokes in patients with symptomatic intracranial stenosis, we determined whether sammpris supported the use. Intracranial stenosis is a common cause of ischaemic strokes, in particular, in the asian, african and hispanic populations. Sammpris trial was lower than seen in the warfarinaspirin symptomatic intracranial disease wasid trial, this risk in either the ptas group or the medically managed group is still unacceptably high, 23%. The results of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial were published recently in the new england journal of medicine. Effect of a balloonexpandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis. However, ptas has not been compared with medical management in a randomized trial. Volume 383, issue 9914, 2531 january 2014, pages 333341.
Have medical therapy and stenting been fairly compared. Outcome in patients previously on antithrombotic therapy in. To remove the trial on a mac, use the acrobat uninstaller in the applicationsadobe. Relationship between risk factor control and vascular events. Middle cerebral artery stenosis in patients with acute. The wingspan stent system approved by the fda under a. We have already had the sammpris trial, which was clearly negative for stent placement, and this trial was stopped at the time when sammpris was published and followup was done. Antithrombotic therapy after acute coronary syndrome or.
Philip meyers has joined his colleagues in taking another look at the 2011 sammpris trial. The sammpris trial results demonstrated that the majority of. Submaximal angioplasty for symptomatic intracranial. Response from the sammpris trial principal investigators. Antiplatelet therapy vs anticoagulation therapy in. From the zeenat qureshi stroke research center, department of neurology, university of minnesota, minneapolis, minnesota aiq, mfks. Enrollment in sammpris was stopped after 451 patients had been randomized primarily because the 30day rate of stroke and death was significantly higher in the stenting arm within 30 days of enrollment. In the sammpris trial stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis, patients were enrolled with tia or stroke in the past 30 days and 70% to 99%. Prevalence, predictors, and prognosis of symptomatic. Management of intracranial atherosclerosis after sammpris. Factors associated with recurrent ischemic stroke in the medical.
We will also address our criticism of the sammpris trial design in order to better design a future trial. This presentation addressessome criticisms of the trial, emphasizes key knowledge gained from the study and proposes potential new directions for research in. Intracranial stenting may be safer in clinical trials vs. Aggressive medical treatment with or without stenting in. It remains unclear whether angioplasty pta alone or in combination with other stent types ptas will yield similar results in perforatorbearing. Design of the vitesse intracranial stent study for. Subgroup analysis of the sammpris trial showed a higher rate of periprocedural perforator strokes with the wingspan stent in the basilar artery in patients with. Similarly, the vissit the vitesse intracranial stent study for ischemic. Recent trials the stenting vs aggressive medical therapy for intracranial arterial stenosis sammpris trial, the carotid occlusion surgery study coss and the vitesse intracranial stent study for ischemic. Importance the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial showed that aggressive medical therapy was more effective. To uninstall your trial version on a windows device, close any open adobe software on your computer, open the windows control panel and doubleclick programs and features.
Background and purpose a multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis icas combined with poor collaterals. Results a total of 227 patients were included in the study, 82 of whom were. The recruitment of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis, an national institute of neurological disorders and stroke. Dec 19, 2007 frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis.
The results of the highly anticipated stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial revealed a 5. The sammpris population was the right patient population to test. Sammpris, short for stenting and aggressive medical management for the prevention of recurrent ischemic stroke, was a large multicenter trial that compared two methods of stroke prevention. Objective to determine baseline features that were associated with a high rate of a primary end point in the medical arm of the sammpris trial. Angioplasty and stenting of intracranial arterial stenosis. In an accompanying editorial, dr joseph p broderick university of cincinnati college of medicine, oh, points out that sammpris is the third recent trial to show no benefit of revascularization. Many factors contributed toward periprocedural stroke in. Angioplasty and stenting of intracranial arterial stenosis in. Frontiers the technique of endovascular intracranial. The sammpris trial suggested that aggressive treatment was superior to endovascular stenting in. Sammpris is an ongoing randomized, multicenter clinical trial funded by the national institute of neurological disorders and stroke. The sammpris trial defined intracranial stenosis based on symptomatology and degree of stenosis.
Director of risk factor management and k23 grant sammpris industry support. Stenting for symptomatic vertebral artery stenosis neurology. The purpose of this study is to report the type and duration of physical activity in the sammpris trial. Comparison of warfarin and aspirin for symptomatic. Download slides article figuresmedia september 15, 2011 n engl j med 2011. The sammpris trial also revealed an interesting point. Multicenter prospective trial of stent placement in. We intend to highlight these past experiences and address future trials and trends in china. Use the search function above to find our free pdf ebooks or use the category list to browse books.
Downloaded from at texas health resources on september 29, 2011. Relationship between risk factor control and vascular. Subgroup analysis of the sammpris trial showed a higher rate of periprocedural perforator strokes with the wingspan stent in the basilar artery in patients with symptomatic intracranial atherosclerotic stenosis icas. Pdf stenting versus aggressive medical therapy for intracranial. Response from the sammpris trial principal investigators regarding. Middle cerebral artery stenosis is not frequent but a wellestablished cause of first and recurrent ischemic stroke. The sammpris trial is also a great example of how cms the centers for medicare and medicaid services can accelerate our understanding of what best practice should be, he added. The study design for the sammpris trial has been published previously. Sep 20, 2010 download the bible, the holy quran, the mahabharata, and thousands of free pdf ebooks on buddhism, meditation, etc. The safety and scientific validity of this study is the. Primary balloon angioplasty for symptomatic, highgrade. The authors conducted a prospective phase i trial designed to assess the safety of submaximal angioplasty in patients with symptomatic icad.
In this prespecified analysis, we aimed to investigate the relationship between risk factor control during followup and outcome of patients in the. As the principal investigators for the stenting and aggressive medical management for the prevention of recurrent ischemic stroke sammpris trial,1 we are compelled to address a few inaccuracies regarding this study in the recent editorial by dr alexander. Balloonexpandable stent vs medical therapy for intracranial. Despite these early promising results, the sammpris trial reported a 30day rate of stroke or death of 14. Stenting for symptomatic intracranial arterial stenosis in.
1531 568 186 1076 876 242 1228 815 511 1145 1442 913 1537 1658 870 1640 770 796 408 1067 157 1188 1135 1066 173 1443 330 585